NEW YORK – Human Longevity said on Wednesday that it has closed a $30 million financing round from a number of investors.
The round included existing investor Emerging Technology Partners as well as new undisclosed healthcare investors.
The San Diego-based company plans to use the proceeds from the financing to enhance its Health Nucleus intelligence platform, which combines brain and body MRI imaging, whole-genome sequencing, and other lab tests such as cardiac CAT scans and metabolic tests with machine learning and artificial intelligence to create "a comprehensive standard for measuring your health and performance."
The platform provides risk analyses for cardiac, cancer, metabolic, and cognitive health issues.
Human Longevity's latest funding round follows a $220 million Series B funding that company completed in 2016.